A medical device OEM was scaling up a drug-delivery platform that relied on custom silicone tubing. The requirements were demanding: tight wall-thickness tolerances, biocompatibility certification, and stable dimensions across a wide temperature range for cold-chain storage.
This was not a standard tubing application. The tubing was part of the fluid path, meaning even a small change in the inner diameter could affect fluid delivery and dosing accuracy.
During the move from prototypes to pilot production, the OEM started seeing inconsistent wall thickness from its existing extrusion supplier. Several production lots were outside specification, but the supplier could not clearly identify why. Repeating the same process was not solving the problem.
With the design freeze approaching and regulatory submission deadlines already defined, the OEM needed more than another extrusion trial. They needed someone who could understand the material, tooling and extrusion process together and find the actual root cause.
The original supplier had successfully produced the tubing during the prototype stage. However, pilot production exposed process variation that had not appeared in the smaller batches.
The main issues were:
Wall-thickness variation beyond specification
Intermittent changes in lumen geometry
No clear root cause after several unsuccessful production lots
Biocompatibility requirements that had to be maintained
A fixed design-freeze date linked to regulatory submission
The risk of having to qualify an entirely new supplier under significant time pressure
For a component that comes into direct contact with a drug formulation, this was more than a cosmetic quality issue. Dimensional variation could affect product performance and dosing accuracy, making it a potential patient-safety concern.
The OEM could not simply accept a "close enough" result.
Instead of treating the problem as a simple extrusion issue, the OEM worked with a manufacturing partner that had both extrusion engineering and material science expertise.
The approach started with understanding why the process was behaving differently, rather than simply running another batch.
The engineering team reviewed the existing extrusion process, including:
Melt temperature profile
Line speed
Cooling conditions
Die geometry
Die swell behaviour
Silicone viscosity and durometer
The team compared these factors against the actual material being used instead of assuming that the existing process settings were still suitable.
The investigation identified die swell as a major contributor to the wall-thickness variation.
The tooling had originally been configured around the characteristics of a different silicone formulation. At prototype volumes, the difference was not obvious. Once the process moved to more consistent pilot-production speeds, the mismatch became much more apparent.
This explained why simply repeating the original process was not producing a reliable result.
Rather than continuing with trial-and-error adjustments, the engineering team recalculated the die geometry based on the actual material behaviour.
Corrected tooling was then manufactured before another production trial was started.
A controlled qualification lot was produced using the revised tooling and process parameters.
This time, wall thickness was monitored continuously using an in-line laser micrometer instead of relying mainly on spot measurements after production.
That provided a much clearer picture of what was happening during the extrusion process.
The engineering and quality teams also rebuilt the supporting documentation, including:
Process validation information
Dimensional inspection data
Material information
Biocompatibility traceability
Qualification records
The documentation was structured so that the OEM could use it within its design history file rather than having to reorganise and reformat raw supplier data.
The important difference was that the team did not simply rerun the process and hope for a better result. The problem was approached from the material, tooling and process perspectives together.
One of the most important parts of the project was communication.
The OEM's project team had direct access to the extrusion engineer. Questions did not have to pass through several layers of customer service before reaching the technical team.
When the die-swell issue was identified, the engineers explained the reasoning behind the conclusion and reviewed the relevant material and process data with the OEM.
This allowed the OEM's own engineering and quality teams to understand the issue rather than simply accepting a supplier's explanation.
Communication also continued throughout the tooling correction and qualification process. Progress updates were provided proactively, and production data from the qualification run was shared as it became available.
That gave the OEM confidence that the corrective action was working before the entire lot was completed.
The revised tooling and process parameters brought the wall-thickness variation back within specification.
The corrected qualification lot passed on the first run, avoiding another cycle of trial-and-error and saving valuable time before the design freeze.
The OEM was also able to maintain its planned regulatory timeline without having to immediately begin qualifying a completely new tubing supplier.
Just as importantly, the documentation was prepared in a format suitable for the OEM's design history file, reducing additional work for its engineering and quality teams.
The project delivered more than a corrected tubing process. It also gave the OEM a better understanding of the material and process sensitivities that could affect the component in future production.
Extrusion equipment alone does not solve every extrusion problem. Understanding how the silicone compound behaves under different processing conditions was essential to identifying the real cause.
The OEM was able to speak directly with the people investigating the problem. This meant faster decisions and fewer communication gaps.
Continuous dimensional monitoring provided real production data instead of relying only on samples taken after the lot was complete.
The qualification information was prepared around the OEM's regulatory and quality requirements, rather than simply providing a collection of raw test results.
The biggest difference was the mindset.
The goal was not to produce another lot and hope it passed.
The goal was to understand why the previous lots failed and eliminate the cause.
That is the difference between supplying medical-grade tubing and providing engineering-led manufacturing support.
Several factors can contribute, including die geometry, material viscosity, die swell, line speed, temperature and cooling conditions.
Die swell can be particularly important because silicone expands as it exits the die. If the tooling is not matched to the actual compound characteristics, the resulting tubing dimensions can vary.
Medical applications typically require tighter control over material selection, biocompatibility, dimensional consistency, traceability and manufacturing documentation.
The requirements become even more important when the tubing is part of a drug or fluid delivery path.
No. It helps detect variation much earlier, but monitoring alone does not solve the underlying problem.
It tells engineers what is changing. Root-cause engineering is still required to determine why it is changing and how to prevent it from happening again.
In many cases, yes.
If the problem is caused by tooling, process parameters or material-process interaction, it may be possible to correct the existing manufacturing process rather than start a completely new supplier qualification.
However, the impact on existing validation and regulatory documentation needs to be assessed carefully.
Do not only ask about extrusion capacity.
Ask about the supplier's:
Material science capability
Extrusion process engineering
Tooling design capability
In-line inspection systems
Process validation experience
Traceability and documentation
Ability to perform root-cause analysis
A capable manufacturing partner should be able to explain why a problem happened and how it will be prevented, not simply offer another production run.
There is no single answer. It depends on the nature of the process change, existing validation, material requirements and regulatory documentation.
For fluid-path-critical components, it is good practice to allow sufficient time before the design freeze for investigation, tooling changes, qualification and documentation.
The earlier a potential extrusion problem is identified, the more options the OEM has.
Medical-grade elastomer tubing may look like a relatively simple component, but the engineering behind reliable tubing can be surprisingly complex.
Material behaviour, tooling, extrusion conditions, dimensional control and regulatory documentation all have to work together.
When a problem appears, the right manufacturing partner does not simply ask, "Can we run another batch?"
The better question is:
"What is causing the variation, and what needs to change so it does not happen again?"
That engineering mindset is what turns a tubing supplier into a reliable manufacturing partner for medical device OEMs.
#MedicalDeviceManufacturing #ElastomerTubing #SiliconeExtrusion #ContractManufacturing #ProcessEngineering #Biocompatibility #MedTechSupplyChain #PrecisionExtrusion #DieSwell #QualityByDesign